Showing results (91-100 of 99) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Molecular Immunology|September 6, 2005
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumorsKlaus Brischwein, Bernd Schlereth, Benjamin Guller, et al.Science (New York, N.Y.)|August 16, 2008
Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyRalf Bargou, Eugen Leo, Gerhard Zugmaier, et al.Journal for Immunotherapy of Cancer|March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALLNaveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.Journal for Immunotherapy of Cancer|February 4, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeuticsThomas M Schmitt, Kelsey Furiya, Cheryl Black, et al.Nature Communications|May 9, 2019
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor responsePatrick A Baeuerle, Jian Ding, Ekta Patel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyMaria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.Molecular Cancer Therapeutics|November 18, 2020
TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid TumorsRichard J Austin, Bryan D Lemon, Wade H Aaron, et al.Blood|October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.Pageof 10